A comprehensive meta-analysis, including SOUL trial data, demonstrated that long-acting GLP-1 RAs reduce the incidence of major adverse cardiovascular events (MACEs), hospitalization for heart failure, kidney events, and all-cause mortality in type 2 diabetes [66]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.